<DOC>
	<DOC>NCT01603251</DOC>
	<brief_summary>The purpose of this study is to determine the safety and impact of ivermectin, administered as single or repeated dose, in combination with artemether-lumefantrine in reducing the proportion of mosquitoes that survive and become infected after feeding on a blood meal from a malaria-infected individual.</brief_summary>
	<brief_title>Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Ivermectin</mesh_term>
	<criteria>asymptomatically infected individuals with any P. falciparum parasite density age &lt; 15 years or &gt; 25 years malaria parasite density ≥ 10,000 parasites/µL clinical symptoms indicating severe malaria axillary temperature ≥ 37.5°C Body Mass Index (BMI) below 18 or above 32 kg/m2 haemoglobin concentration below 11 g/dL taken ivermectin in the last three months Loa loa as assessed by questionnaire, clinical examination and parasitological assessments for women: pregnancy or lactation known hypersensitivity to AL or IVM history and/or symptoms indicating chronic illness current use of tuberculosis or antiretroviral medication unable to give written informed consent unwillingness to participate in two membrane feeding assays travel history to Angola, Cameroon, Chad, Central African Republic, Congo, DR Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria and Sudan. If a potential participant has ever visited one or more of these countries, he or she will not be eligible for enrolment. history of cardiovascular disease. taking drugs that are known to influence cardiac function and to prolong QTc interval, such as class IA and III: neuroleptics, antidepressant agents, certain antibiotics including some agents of the following classes macrolides, fluoroquinolones, imidazole, and triazole antifungal agents, certain nonsedating antihistaminics (terfenadine, astemizole) and cisapride. known disturbances of electrolyte balance, e.g. hypokalaemia or hypomagnesaemia. taking drugs which may be metabolized by cytochrome enzyme CYP2D6 (e.g., flecainide, metoprolol, imipramine, amitriptyline, clomipramine).</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>transmission</keyword>
	<keyword>anopheles</keyword>
</DOC>